Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
56 /100
HIGH RISK
Score updated Aug 28, 2026

GTBP — GT Biopharma, Inc. Dilution Risk Tracker

Track GTBP dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track GTBP — Get alerts when the score changes →

As of August 28, 2026, GT Biopharma, Inc. (GTBP) has a DilutionWatch DilutionScore of 56/100, rated HIGH dilution risk. GT Biopharma, Inc. has a market capitalization of $17.25M, 45.11M shares outstanding, 41 institutional holders tracked. Stored dilution-related fields include 21.1K outstanding warrants.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
80
💰 Cash Runway
40
📊 Float Risk
30
⚠️ Warrant Exposure
15
🔄 Convertible Debt
15

Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
model est. 27%
🔄 Reverse Split model est. 55%
• 50-day avg $0.39 below $1 exchange minimum
🔔 Track GTBP — Get forecast alerts →

Market Data

Market Cap$17.25M
Shares Outstanding45.11M
Float33.53M
Cash$12.82M
DebtN/A
Short InterestN/A

Institutional Holdings

QoQ: ↑ 329.9% shares (2026Q1 vs prior)
41 institutional holders · 2.08M shares
#1 VANGUARD CAPITAL MANAGEMENT LLC 903.8K shares
#2 GEODE CAPITAL MANAGEMENT, LLC 294.5K shares
#3 VANGUARD FIDUCIARY TRUST CO 225.9K shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest3.92M
Days to Cover7.8
% of Float11.7%
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2025-12-31
xbrl XBRL CONVERTIBLE 2022-12-31
S-1 SHELF 2026-04-30
424B3 ATM 2026-01-30
EFFECT EFFECT 2026-01-30
Full SEC filing analysis available with free account

Recent News

No recent news

Factual GTBP Dilution Snapshot

GT Biopharma, Inc. (GTBP) has a DilutionScore of 56/100, rated High dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track GTBP Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking GTBP — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for GTBP
GTBP FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.